Related Experiment Video
Updated: Jun 11, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.0K
Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study
Jungsoo Lee1,2, Youngbeom Kim3,4, Kihyuk Shin1,2
1Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea.
Allergy, Asthma & Immunology Research
|October 4, 2024
Summary
Upadacitinib significantly improved symptoms for patients with refractory prurigo nodularis (PN), a chronic skin condition causing severe itching. This treatment offers a well-tolerated alternative for patients unresponsive to other therapies.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Prurigo nodularis (PN) is a chronic neuroinflammatory skin condition characterized by intense pruritus.
- Conventional treatments for PN often show limited efficacy, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy and safety of upadacitinib in patients with refractory prurigo nodularis.
- To assess the impact of upadacitinib on pruritus, disease severity, and quality of life.
Main Methods:
- A prospective study involving ten patients with refractory PN.
- Upadacitinib was administered daily at 15 mg for 24 weeks, following screening for chronic infections.
- Treatment response was measured using the itch Numeric Rating Scale (NRS), investigator's Global Assessment (IGA), and Dermatology Life Quality Index (DLQI).
Main Results:
- Significant reductions in IGA (3.4 to 1.0), DLQI (17.8 to 0.6), and itch NRS (8.1 to 0.8) scores were observed after 24 weeks.
- All ten patients had previously shown limited response to systemic cyclosporine.
- No severe adverse events were reported during the study period.
Conclusions:
- Upadacitinib demonstrates significant efficacy in reducing pruritus and improving disease severity and quality of life in patients with refractory PN.
- Upadacitinib presents a well-tolerated alternative therapeutic option for managing chronic and treatment-resistant prurigo nodularis.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
152
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
152
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
155
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
01:30Skin Cancer
4.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.0K